

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 7/40, C12M 1/00		A2	(11) International Publication Number: WO 98/05792
			(43) International Publication Date: 12 February 1998 (12.02.98)
(21) International Application Number: PCT/US97/14191			(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).
(22) International Filing Date: 25 July 1997 (25.07.97)			
(30) Priority Data: 08/691,071 1 August 1996 (01.08.96) US 08/843,370 15 April 1997 (15.04.97) US			(81) Designated States: AT, BR, CA, CH, CN, DE, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(60) Parent Applications or Grants (63) Related by Continuation US 08/691,071 (CIP) Filed on 1 August 1996 (01.08.96) US 08/843,370 (CIP) Filed on 15 April 1997 (15.04.97)			Published Without international search report and to be republished upon receipt of that report.
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): AKERBLOM, Ingrid, E. [US/US]; 1234 Johnson Street, Redwood City, CA 94061 (US).			

(54) Title: A NOVEL HUMAN LEPTIN RECEPTOR GENE-RELATED PROTEIN

Human Leptin Receptor cDNA: +1, +194 ATG, coding sequence

LRFP cDNA: +12, +82 ATG, +145 ATG, +173 Splice, coding sequence

C. elegans ORF C30B5.2 cDNA: +12, +173 Splice, coding sequence

* Numbering relative to human leptin receptor
Hatched area represents identical sequences

(57) Abstract

The present invention provides a polynucleotide which identifies and encodes a novel human leptin receptor gene-related protein (LRGRP). The invention also provides expression vectors, host cells, agonists, and antagonists. The invention also provides methods for treating metabolic, reproductive, connective tissue and reproductive disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A NOVEL HUMAN LEPTIN RECEPTOR GENE-RELATED PROTEIN

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of a novel human leptin receptor gene-related protein and to the use of these sequences in the diagnosis, prevention, and treatment of cancer and disorders in energy metabolism, reproduction, connective tissues, and development.

BACKGROUND ART

The *obese* (*ob*) gene product, leptin, is an important circulating signal for the regulation of body weight (Zhang Y. et al. (1994) *Nature* 372:425-432). Mice homozygous for a nonfunctional *ob* gene become morbidly obese and diabetic, due to overeating and increased metabolic efficiency. In 1995, Tartaglia L.A. et al. (*Cell* 83:1263-1271) described a high affinity receptor for murine leptin (OB-R). Evidence suggests that the weight-reducing effects of leptin may be mediated by signal transduction through OB-R in the hypothalamus (Lee G.H. et al. (1996) *Nature* 379:632-635). In addition to reducing appetite, leptin has been found to ablate body fat in rats (Chen G. et al. (1996) *Proc. Natl. Acad. Sci.* 93:14795-14799). The injection of a leptin-expressing adenoviral vector resulted in reduced body fat relative to rats that did not receive the leptin-expressing vector, but which ate an equivalent amount of food.

Regulation in the expression of splice variants can have an important role in the activity of signal transduction molecules and has been implicated in the pathogenesis of several diseases (Khachigian L.M. et al. (1992) *Pathology* 24:280-290). For example, mutations that create new splice variants of the sulfonylurea receptor gene segregate with familial persistent hyperinsulinemic hypoglycemia (Thomas P.M. et al. (1995) *Science* 268:426-429).

At least nine alternatively spliced forms of mouse OB-R have been described (Lee et al., *supra*). A splice variant, B219, is expressed in the mouse yolk sac, early fetal liver, enriched hematopoietic stem cells, a variety of lympho-hematopoietic cells lines, and in adult reproductive organs and may be directly involved in hematopoiesis and reproduction (Cioffi J.A. et al. (1996) *Nature Medicine* 2:585-589). Further evidence of a role for leptin

in hematopoiesis was recently reported by Gainsford T. et al., who found that leptin enhances cytokine production and phagocytosis of parasites by murine peritoneal macrophages (1996, Proc. Natl. Acad. Sci. 93:14564-14568). Additional support for a leptin role in reproduction comes from Chehab F.F. et al, who report that treatment with leptin corrects a sterility defect in ob/ob female mice (1996, Nature Genet. 12:318-320). The researchers showed that leptin brings on fertility by restoring necessary hypothalamic and pituitary hormone levels rather than by fat reduction.

Recently, leptin has been implicated in the induction of puberty in both mice and humans. Female mice treated with regular injections of leptin reach sexual maturity 37 days after birth, whereas untreated mice show signs of sexual maturity at about 40 days after birth (Chehab F. et al., (1997) Science 275:88-90). While in humans, leptin levels increase sharply at the same time that testosterone levels increase in boys undergoing puberty (Flier J., unpublished).

OB-R mutations that create alternatively spliced transcripts are responsible for the severely obese and diabetic phenotype of db/db mice (Chen H. et al. (1996) Cell 84:491-495) and of fa/fa Zucker rats (Chua S.C. et al. (1996) Science 271:994-996). Based on synteny between human and mouse chromosomes, the human version of OB-R is likely to map to human chromosome 1p31 (Lee et al., supra).

Genome sequencing efforts in Caenorhabditis elegans and Saccharomyces cerevisiae have revealed putative open reading frames (ORFs) C30B5.2 and YJR044c, respectively (Wilson R. et al., (1994) Nature 368:32-38; Huang M.E. et al. (1995) Yeast 11: 775-781). YJR044c and C30B5.2 are 27% identical and 71% similar in amino acid sequence and share a similar pattern of hydrophobicity. YJR044c has been characterized as a putative membrane associated protein (Wilson et al, supra). The C30B5.2 amino acid sequence has a consensus pattern (CCxxHxxC) for phospholipase A2, a family of enzymes that release fatty acids from the second carbon group of glycerol.

The activity of many signal transduction molecules, such as the leptin receptor, is thought to be regulated by the expression of splice variants of the molecule. A new leptin receptor gene-related protein could provide the basis for diagnosis and treatment of cancer, and disorders in energy metabolism, reproduction, connective tissues, and development.

DISCLOSURE OF THE INVENTION

The present invention discloses a novel human leptin receptor gene-related protein (hereinafter referred to as LRGRP), which shares part of its nucleic acid coding sequences with a non-coding region of human leptin receptor cDNA (GI 1139595). In addition, it has
5 homology to the membrane associated proteins of *C. elegans* ORF C30B5.2 (GI 733555) and *S. cerevisiae* ORF YJR044c (GI 1197072). Accordingly, the invention features a substantially purified leptin receptor gene-related protein, as shown in the amino acid sequence of SEQ ID NO:1. The invention also relates to a polypeptide as shown in SEQ ID NO:1 from Met₂₂ through Trp₁₃₁, as well as other fragments of SEQ ID NO:1.

10 One aspect of the invention features isolated and substantially purified polynucleotides which encode LRGRP. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2. In addition, the invention features polynucleotide sequences that hybridize under stringent conditions to a fragment of SEQ ID NO:2, from nucleotides C₁₆₃ to A₈₇₄, inclusive.

15 The invention further relates to nucleic acid sequence encoding LRGRP, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotide sequences encoding LRGRP. The present invention also relates to antibodies which bind specifically to LRGRP, pharmaceutical compositions comprising substantially purified LRGRP,
20 fragment thereof, agonists, or alternatively, antagonists of LRGRP, in conjunction with a suitable pharmaceutical carrier, and methods for producing LRGRP, fragments thereof, agonists, or antagonists of LRGRP. The invention also features methods for treating cancer and connective tissue disorders by administering an antagonist to LRGRP and methods for treating metabolic, reproductive and developmental disorders by administering an agonist to
25 LRGRP.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A, 1B and 1C show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of the novel leptin receptor gene-related protein, LRGRP produced using MacDNAsis software (Hitachi Software Engineering Co Ltd).

30 Figure 2 shows the northern analysis for Incyte Clone 492703 (SEQ ID NO:2) produced electronically using LIFESEQ™ database (Incyte Pharmaceuticals, Palo Alto CA). The percentage abundance is calculated by multiplying the number of transcripts

found in the library times 100 and dividing the product by the total number of transcripts in the library.

Figure 3 shows a schematic diagram of the cDNAs of human leptin receptor gene, LRGRP, and *C. elegans* ORF C30B5.2, highlighting similarities and differences in selected splice sites and coding sequences.

Figure 4 shows the amino acid sequence alignments among LRGRP (SEQ ID NO:1), *C. elegans* ORF C30B5.2 (GI 733555; SEQ ID NO:3), and *S. cerevisiae* ORF YJR044c (GI 1197072; SEQ ID NO:4) produced using the multisequence alignment program of DNASTar software (DNASTar Inc, Madison WI).

Figure 5 shows the hydrophobicity plot (generated using MacDNAsis software) for LRGRP, SEQ ID NO:1; the X axis reflects amino acid position, and the negative Y axis, hydrophobicity (Figs. 5 and 6).

Figure 6 shows the hydrophobicity plot for *C. elegans* ORF C30B5.2, SEQ ID NO:3.

Figure 7 shows the genomic organization of the gene encoding human LRGRP and nucleotide sequences of the exon/intron junctions.

Figure 8 shows a schematic representation of the LRGRP, OB-R, and B219 transcripts with PCR primers, P1-P4, shown at their respective annealing sites, indicates the lengths of the expected PCR products.

Figure 9 shows an agarose gel in which the following samples were run: 100 bp DNA ladders and PCR products from six hematopoietic (CAM, Raji, HL60, HSB2, Jurkat, and K562), a cervical cancer (Hela), human brown pre-adipocyte, and adipocyte cell lines. The sizes of the PCR products are indicated with arrows.

MODES FOR CARRYING OUT THE INVENTION

Definitions

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Similarly, amino acid sequence as used herein refers to peptide or protein sequence.

"Peptide nucleic acid" as used herein refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine, and an amino group have been

added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary (template) strand of nucleic acid (Nielsen PE et al (1993) Anticancer Drug Des 8:53-63).

As used herein, LRGRP refers to the amino acid sequence of substantially purified LRGRP obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic or recombinant.

A "variant" of LRGRP is defined as an amino acid sequence that is different by one or more amino acid "substitutions". The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, eg, replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, eg, replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTar software.

The term "biologically active" refers to a LRGRP having structural, regulatory or biochemical functions of a naturally occurring LRGRP. Likewise, "immunologically active" defines the capability of the natural, recombinant or synthetic LRGRP, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "derivative" as used herein refers to the chemical modification of a nucleic acid encoding LRGRP or the encoded LRGRP. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a polypeptide which retains essential biological characteristics of natural LRGRP.

The term "agonist", as used herein, refers to a molecule which, when bound to LRGRP, causes a change in LRGRP which modulates the activity of LRGRP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to LRGRP.

The terms "antagonist" or "inhibitor", as used herein, refer to a molecule which, when bound to LRGRP, blocks or modulates the biological or immunological activity of

LRGRP. Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to LRGRP.

As used herein, the term "substantially purified" refers to molecules, either nucleic or amino acid sequences, that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.

"Stringency" typically occurs in a range from about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe) to about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a stringent hybridization can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or related polynucleotide sequences.

The term "hybridization" as used herein shall include "any process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY). Amplification as carried out in the polymerase chain reaction technologies is described in Dieffenbach CW and GS Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY).

A "deletion" is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

An "insertion" or "addition" is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring LRGRP.

A "substitution" results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively.

Description

The invention is based on the discovery of a novel human leptin receptor gene-related protein, (LRGRP), the polynucleotides encoding LRGRP, and the use of these compositions for the diagnosis, prevention, or treatment of cancer, and metabolic, reproductive, connective tissue, and developmental disorders.

Nucleic acids encoding the human LRGRP of the present invention were first identified in Incyte Clone 492703 from the hNT2 cell line cDNA library (HNT2NOT01) through a computer-generated search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the extended nucleic acid sequences of Incyte

cDNAs encoding a portion of LRGRP were found in cDNA libraries derived from the tissues and cell lines shown in Figure 2. Portions of cDNAs unique to LRGRP were found in heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, and brain tissues. PCR analysis also showed that cDNAs specifically encoding LRGRP and cDNAs specifically encoding leptin receptor are also found in human pre-adipocyte cell line both before and after differentiation, as well as in six hematopoietic cell lines and a cervical cancer cell line (Figures 8 and 9). Naturally occurring expression of LRGRP is not necessarily limited to these cell and tissue types.

The present invention also encompasses LRGRP variants. A preferred LRGRP variant is one having at least 80% amino acid sequence similarity to the LRGRP amino acid sequence (SEQ ID NO:1), a more preferred LRGRP variant is one having at least 90% amino acid sequence identity to SEQ ID NO:1 and a most preferred LRGRP variant is one having at least 95% amino acid sequence identity to SEQ ID NO:1.

Nucleic acid encoding the human leptin receptor gene-related protein of the present invention was first identified in cDNA, Incyte Clone 492703 (SEQ ID NO:2), through a computer-generated search for nucleic acid sequence alignments. The nucleic acid sequence of SEQ ID NO:2 encodes the LRGRP amino acid sequence, SEQ ID NO:1 and shares some exons with the non-coding regions of human leptin receptor cDNAs (Tartaglia et al, supra; Fig. 3). Nucleotides G₁ to G₁₆₂ of SEQ ID NO:2 are identical to nucleotides G₁₂ to G₁₇₃ in the non-coding region of human leptin receptor cDNA (GI 1139595; Tartaglia et al, supra). The coding sequence of LRGRP is unique. Nucleic acids at a putative splice site in LRGRP, the 3' end of the region of identity with human leptin receptor, encode amino acids that align precisely with those encoded at a putative splice site for the related gene *C. elegans* ORF C30B5.2 (GI 733555; Wilson et al, supra; Figure 3). An exon in the non-coding region of the rat leptin receptor cDNA (GI 1335914) has a high degree of homology to the portion of the LRGRP coding sequence that matches the non-coding sequence of the human leptin receptor. The LRGRP gene maps to the same site as the leptin receptor, human chromosome 1p31. The genomic organization of the gene encoding LRGRP and the sequence of the exon/intron junctions are shown in Figure 7.

In one embodiment of the present invention, translation of the LRGRP mRNA starts at the ATG that begins at A₇₁ of SEQ ID NO:2. In another embodiment, translation of the

LRGRP mRNA starts at the following in-frame ATG that begins at A₁₃₄. The present invention is based, in part, on the chemical and structural homology among LRGRP, *C. elegans* ORF C30B5.2 (GI 733555), and *S. cerevisiae* ORF YJR044c (GI 1197072; Huang et al, supra; Figure 4). LRGRP has 45% identity and 77% similarity to the amino acid sequence of *C. elegans* ORF C30B5.2. LRGRP has 32% identity and 64% similarity to the amino acid sequence of *S. cerevisiae* ORF YJR044c. LRGRP and the *C. elegans* ORF C30B5.2 hydrophobicity plots (shown in Figures 5 and 6) suggests LRGRP shares configuration and membrane localization. The novel LRGRP is 131 amino acids long and has no putative glycosylation sites.

The LRGRP Coding Sequences

The nucleic acid and deduced amino acid sequences of LRGRP are shown in Figures 1A, 1B and 1C. In accordance with the invention, any nucleic acid sequence which encodes the amino acid sequence of LRGRP can be used to generate recombinant molecules which express LRGRP. In a specific embodiment described herein, a nucleotide sequence encoding a portion of LRGRP was first isolated as Incyte Clone 492703 from a hNT2 cell cDNA library (HNT2NOT01).

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of LRGRP-encoding nucleotide sequences, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene may be produced. The invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring LRGRP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode LRGRP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring LRGRP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding LRGRP or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding LRGRP and its derivatives without

altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

It is now possible to produce a DNA sequence, or portions thereof, encoding a LRGRP and its derivatives entirely by synthetic chemistry, after which the synthetic gene may be inserted into any of the many available DNA vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding LRGRP or any portion thereof.

Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of Figures 1A, 1B and 1C, or fragments thereof, under various conditions of stringency. Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex or probe, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA) incorporated herein by reference, and may be used at a defined stringency.

Altered nucleic acid sequences encoding LRGRP which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent LRGRP. The protein may also show deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent LRGRP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of LRGRP is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine, threonine phenylalanine, and tyrosine.

Included within the scope of the present invention are alleles of LRGRP. As used herein, an "allele" or "allelic sequence" is an alternative form of LRGRP. Alleles result from a mutation, ie, a change in the nucleic acid sequence, and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given

gene may have none, one or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

5 Methods for DNA sequencing are well known in the art and employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland OH)), Taq polymerase (Perkin Elmer, Norwalk CT), thermostable T7 polymerase (Amersham, Chicago IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by
10 Gibco BRL (Gaithersburg MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the ABI 377 DNA sequencers (Perkin Elmer).

Extending the Polynucleotide Sequence

15 The polynucleotide sequence encoding LRGRP may be extended utilizing partial nucleotide sequence and various methods known in the art to detect upstream sequences such as promoters and regulatory elements. Gobinda et al (1993; PCR Methods Applic 2:318-22) disclose "restriction-site" polymerase chain reaction (PCR) as a direct method which uses universal primers to retrieve unknown sequence adjacent to a known locus. First, genomic DNA is amplified in the presence of primer to a linker sequence and a
20 primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

25 Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia T et al (1988) Nucleic Acids Res 16:8186). The primers may be designed using OLIGO® 4.06 Primer Analysis Software (1992; National Biosciences Inc, Plymouth MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a
30 suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

 Capture PCR (Lagerstrom M et al (1991) PCR Methods Applic 1:111-19) is a

method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before PCR.

5 Another method which may be used to retrieve unknown sequences is that of Parker JD et al (1991; Nucleic Acids Res 19:3055-60). Additionally, one can use PCR, nested primers and PromoterFinder libraries to walk in genomic DNA (PromoterFinder™ Clontech (Palo Alto CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions. Preferred libraries for screening for full length cDNAs are
10 ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5' and upstream regions of genes. A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5' nontranslated regulatory region.

15 Capillary electrophoresis may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. Systems for rapid sequencing are available from Perkin Elmer, Beckman Instruments (Fullerton CA), and other companies. Capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the
20 emitted wavelengths by a charge coupled device camera. Output/light intensity is converted to electrical signal using appropriate software (eg. Genotyper™ and Sequence Navigator™ from Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display is computer controlled. Capillary electrophoresis is particularly suited to the sequencing of small pieces of DNA which might be present in limited amounts
25 in a particular sample. The reproducible sequencing of up to 350 bp of M13 phage DNA in 30 min has been reported (Ruiz-Martinez MC et al (1993) Anal Chem 65:2851-8).

Expression of the Nucleotide Sequence

30 In accordance with the present invention, polynucleotide sequences which encode LRGRP, fragments of the polypeptide, fusion proteins or functional equivalents thereof may be used in recombinant DNA molecules that direct the expression of LRGRP in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid

sequence, may be used to clone and express LRGRP. As will be understood by those of skill in the art, it may be advantageous to produce LRGRP-encoding nucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular prokaryotic or eukaryotic host (Murray E et al (1989) Nuc Acids Res 17:477-508) can be selected, for example, to increase the rate of LRGRP expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered in order to alter a LRGRP coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, eg, site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns, to change codon preference, to produce splice variants, etc.

In another embodiment of the invention, a natural, modified or recombinant polynucleotides encoding LRGRP may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for inhibitors of LRGRP activity, it may be useful to encode a chimeric LRGRP protein that is recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between a LRGRP sequence and the heterologous protein sequence, so that the LRGRP may be cleaved and purified away from the heterologous moiety.

In an alternate embodiment of the invention, the coding sequence of LRGRP may be synthesized, whole or in part, using chemical methods well known in the art (see Caruthers MH et al (1980) Nuc Acids Res Symp Ser 215-23, Horn T et al (1980) Nuc Acids Res Symp Ser 225-32, etc). Alternatively, the protein itself could be produced using chemical methods to synthesize a LRGRP amino acid sequence, whole or in part. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge JY et al (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.

The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography (eg, Creighton (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co, New York NY). The composition of the

synthetic peptides may be confirmed by amino acid analysis or sequencing (eg, the Edman degradation procedure; Creighton, supra). Additionally the amino acid sequence of LRGRP, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

Expression Systems

In order to express a biologically active LRGRP, the nucleotide sequence encoding LRGRP or its functional equivalent, is inserted into an appropriate expression vector, ie, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art can be used to construct expression vectors containing a LRGRP coding sequence and appropriate transcriptional or translational controls. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination or genetic recombination. Such techniques are described in Sambrook et al (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY and Ausubel FM et al (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY.

A variety of expression vector/host systems may be utilized to contain and express a LRGRP coding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (eg, baculovirus); plant cell systems transfected with virus expression vectors (eg, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (eg, Ti or pBR322 plasmid); or animal cell systems.

The "control elements" or "regulatory sequences" of these systems vary in their strength and specificities and are those nontranslated regions of the vector, enhancers, promoters, and 3' untranslated regions, which interact with host cellular proteins to carry out transcription and translation. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid

(Stratagene, LaJolla CA) or pSport1 (Gibco BRL) and ptrp-lac hybrids and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (eg, heat shock, RUBISCO; and storage protein genes) or from plant viruses (eg, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from the mammalian genes or from mammalian viruses are most appropriate. If it is necessary to generate a cell line that contains multiple copies of LRGRP, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for LRGRP. For example, when large quantities of LRGRP are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as Bluescript® (Stratagene), in which the LRGRP coding sequence may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke & Schuster (1989) J Biol Chem 264:5503-5509); and the like. pGEX vectors (Promega, Madison WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems are designed to include heparin, thrombin or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel et al (supra) and Grant et al (1987) Methods in Enzymology 153:516-544.

In cases where plant expression vectors are used, the expression of a sequence encoding LRGRP may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV (Brisson et al (1984) Nature 310:511-514) may be used alone or in combination with the omega leader sequence from TMV (Takamatsu et al (1987) EMBO J 6:307-311). Alternatively, plant promoters such as

the small subunit of RUBISCO (Coruzzi et al (1984) EMBO J 3:1671-1680; Broglie et al (1984) Science 224:838-843); or heat shock promoters (Winter J and Sinibaldi RM (1991) Results Probl Cell Differ 17:85-105) may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see Hobbs S or Murry LE in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill New York NY, pp 191-196 or Weissbach and Weissbach (1988) Methods for Plant Molecular Biology, Academic Press, New York NY, pp 421-463.

An alternative expression system which could be used to express LRGRP is an insect system. In one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The LRGRP coding sequence may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of LRGRP will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect S. frugiperda cells or Trichoplusia larvae in which LRGRP is expressed (Smith et al (1983) J Virol 46:584; Engelhard EK et al (1994) Proc Nat Acad Sci 91:3224-7).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a LRGRP coding sequence may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing LRGRP in infected host cells (Logan and Shenk (1984) Proc Natl Acad Sci 81:3655-59). In addition, transcription enhancers, such as the rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be required for efficient translation of a LRGRP sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where LRGRP, its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure

transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf D et al (1994) Results Probl Cell Differ 20:125-62; Bittner et al (1987) Methods in Enzymol 153:516-544).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, etc have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express LRGRP may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M et al (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy I et al (1980) Cell 22:817-23) genes which can be employed in tk- or aprt- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler M et al (1980) Proc Natl Acad Sci 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin F et al (1981) J Mol Biol 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry,

supra). Additional selectable genes have been described, for example, *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine (Hartman SC and RC Mulligan (1988) Proc Natl Acad Sci 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate, GUS, and luciferase and its substrate, luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes CA et al (1995) Methods Mol Biol 55:121-131).

Identification of Transformants Containing the Polynucleotide Sequence

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression should be confirmed. For example, if the LRGRP is inserted within a marker gene sequence, recombinant cells containing LRGRP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a LRGRP sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem LRGRP as well.

Alternatively, host cells which contain the coding sequence for LRGRP and express LRGRP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of the nucleic acid or protein.

The presence of the polynucleotide sequence encoding LRGRP can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of polynucleotides encoding LRGRP. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the LRGRP-encoding sequence to detect transformants containing DNA or RNA encoding LRGRP. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides which can be used as a probe or amplimer. A variety of protocols for detecting and measuring the expression of LRGRP, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples

include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on LRGRP is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton R et al (1990, Serological Methods, a Laboratory Manual, APS Press, St Paul MN) and Maddox DE et al (1983, *J Exp Med* 158:1211).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding LRGRP include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the LRGRP sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides.

A number of companies such as Pharmacia Biotech (Piscataway NJ), Promega (Madison WI), and US Biochemical Corp (Cleveland OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in US Patent No. 4,816,567 incorporated herein by reference.

Purification of LRGRP

Host cells transformed with a nucleotide sequence encoding LRGRP may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides encoding LRGRP can be designed with signal sequences which direct secretion of LRGRP through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may join LRGRP to nucleotide sequence encoding a polypeptide domain which will facilitate

purification of soluble proteins (Kroll DJ et al (1993) DNA Cell Biol 12:441-53; cf discussion of vectors infra containing fusion proteins).

LRGRP may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor XA or enterokinase (Invitrogen, San Diego CA) between the purification domain and LRGRP is useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising an LRGRP and contains nucleic acid encoding 6 histidine residues followed by thioredoxin and an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography as described in Porath et al (1992) Protein Expression and Purification 3:263-281) while the enterokinase cleavage site provides a means for purifying LRGRP from the fusion protein.

In addition to recombinant production, fragments of LRGRP may be produced by direct peptide synthesis using solid-phase techniques (cf Stewart et al (1969) Solid-Phase Peptide Synthesis, WH FREEMAN Co, San Francisco; Merrifield J (1963) J Am Chem Soc 85:2149-2154). In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City CA) in accordance with the instructions provided by the manufacturer. Various fragments of LRGRP may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

Uses of LRGRP

There are shared exons between polynucleotides of the non-coding region of the leptin receptor (GI 1139595; Tartaglia et al, supra) and a portion of the coding region of LRGRP. In addition, there is chemical and structural homology among LRGRP and the C. elegans and S. cerevisiae ORFs, two genes that appear to be localized to the membrane. Accordingly, LRGRP or a LRGRP derivative may be used for diagnosis and treatment of cancer and metabolic, reproductive, connective tissue and developmental disorders.

Additionally, since induced expression of leptin in rats results in muscle with significantly reduced fat content, LRGRP, a LRGRP derivative, or a vector expressing LRGRP could be used to produce lean meat in livestock.

LRGRP appears to be a membrane protein and thus not soluble. Therefore, in order to allow administration to a patient in need, it is desirable to develop a soluble agonist to LRGRP by techniques known in the art. Therefore, in one embodiment, an agonist of LRGRP may be administered to a subject to treat a metabolic disorder. Such disorders may include, but are not limited to, obesity, diabetes, hypercholesterolemia, and hyperlipidemia.

In another embodiment, an agonist of LRGRP may be administered to a subject to treat a male or female reproductive disorder. Such disorders may include, but are not limited to, infertility, hypogonadism, and amenorrhea.

In another embodiment, an agonist of LRGRP may be administered to a subject to treat a developmental disorder. Such disorders may include, but are not limited to, spina bifida, hematopoietic syndrome from radiation, immunologic deficiency diseases, dwarfism, neural tube defects, arthrogryposis multiplex congenita, and musculoskeletal defects.

LRGRP is expressed in several cancer cell lines and tumor tissues. Therefore, antagonists of LRGRP may either indirectly or directly interfere with tumor cell growth. Thus, in one embodiment, an antagonist of LRGRP may be administered to a subject to treat cancer. Such cancers may include, but are not limited to, adenocarcinoma, sarcoma, leukemia, lymphoma, and cancers of the brain, breast, and bladder.

LRGRP is expressed in the synovial tissue of an arthritis patient. Thus, in another embodiment, an antagonist of LRGRP may be administered to a subject to treat a connective tissue disorder. Such disorders include, but are not limited to, rheumatoid arthritis and Sjogren's syndrome.

In another embodiment, a vector capable of expressing LRGRP, or a fragment or a derivative thereof, may also be administered to a subject to treat any of the metabolic, reproductive, or developmental disorders listed above. In another aspect, antibodies which are specific for LRGRP may be used directly as an antagonist of LRGRP.

In those conditions where leptin receptor gene-related protein activity is not desirable, cells could be transfected with antisense sequences of LRGRP-encoding polynucleotides or provided with inhibitors of LRGRP.

LRGRP Antibodies

LRGRP-specific antibodies are useful for the diagnosis and treatment of conditions and diseases associated with expression of LRGRP, and with metabolic, reproductive, and developmental disorders. In particular, LRGRP-specific antibodies may be use as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express LRGRP. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library. Neutralizing antibodies, ie, those which inhibit dimer formation, are especially preferred for diagnostics and therapeutics.

LRGRP for antibody induction does not require biological activity; however, the protein fragment, or oligopeptide must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids. Preferably, they should mimic a portion of the amino acid sequence of the natural protein and may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of LRGRP amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule. Procedures well known in the art can be used for the production of antibodies to LRGRP.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc may be immunized by injection with LRGRP or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are potentially useful human adjuvants.

Monoclonal antibodies to LRGRP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein (1975 Nature 256:495-497), the human B-cell hybridoma technique (Kosbor et al (1983) Immunol Today 4:72; Cote et al (1983) Proc Natl Acad Sci 80:2026-2030) and the EBV-hybridoma technique (Cole et al (1985) Monoclonal

Antibodies and Cancer Therapy, Alan R Liss Inc, New York NY, pp 77-96).

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison et al (1984) Proc Natl Acad Sci 81:6851-6855; Neuberger et al (1984) Nature 312:604-608; Takeda et al (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies (US Patent No. 4,946,778) can be adapted to produce LRGRP-specific single chain antibodies

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al (1989, Proc Natl Acad Sci 86: 3833-3837), and Winter G and Milstein C (1991; Nature 349:293-299).

Antibody fragments which contain specific binding sites for LRGRP may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse WD et al (1989) Science 256:1275-1281).

A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the formation of complexes between LRGRP and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific LRGRP protein is preferred, but a competitive binding assay may also be employed. These assays are described in Maddox DE et al (1983, J Exp Med 158:1211).

Diagnostic Assays Using LRGRP Specific Antibodies

Particular LRGRP antibodies are useful for the diagnosis of conditions or diseases characterized by expression of LRGRP or in assays to monitor patients being treated with LRGRP, agonists or inhibitors. Diagnostic assays for LRGRP include methods utilizing the antibody and a label to detect LRGRP in human body fluids or extracts of cells or tissues.

The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known, several of which were described above.

5 A variety of protocols for measuring LRGRP, using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on LRGRP is preferred, but
10 a competitive binding assay may be employed. These assays are described, among other places, in Maddox, DE et al (1983, J Exp Med 158:1211).

 In order to provide a basis for diagnosis, normal or standard values for LRGRP expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with antibody to LRGRP
15 under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by comparing various artificial membranes containing known quantities of LRGRP with both control and disease samples from biopsied tissues. Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by disease.
20 Deviation between standard and subject values establishes the presence of disease state.

Drug Screening

 LRGRP, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The fragment employed in such a test may be free in solution, affixed to a solid support,
25 borne on a cell surface, or located intracellularly. The formation of binding complexes, between LRGRP and the agent being tested, may be measured.

 Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the LRGRP is described in detail in "Determination of Amino Acid Sequence Antigenicity" by Geysen
30 HN, WO Application 84/03564, published on September 13, 1984, and incorporated herein by reference. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test

compounds are reacted with fragments of LRGRP and washed. Bound LRGRP is then detected by methods well known in the art. Purified LRGRP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding LRGRP specifically compete with a test compound for binding LRGRP. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with LRGRP.

Uses of the Polynucleotide Encoding LRGRP

A polynucleotide encoding LRGRP, or any part thereof, may be used for diagnostic and/or therapeutic purposes. In a preferred embodiment, the polynucleotide used for diagnostic purpose is from nucleotides C₁₆₃ to A₈₇₄ of SEQ ID NO:2. For diagnostic purposes, polynucleotides encoding LRGRP of this invention may be used to detect and quantitate gene expression in biopsied tissues in which expression of LRGRP may be implicated. The diagnostic assay is useful to distinguish between absence, presence, and excess expression of LRGRP and to monitor regulation of LRGRP levels during therapeutic intervention. Included in the scope of the invention are oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs.

Another aspect of the subject invention is to provide for hybridization or PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding LRGRP or closely related molecules. The specificity of the probe, whether it is made from a highly specific region, eg, 10 unique nucleotides in the 5' regulatory region, or a less specific region, eg, especially in the 3' region, and the stringency of the hybridization or amplification (maximal, high, intermediate or low) will determine whether the probe identifies only naturally occurring sequences encoding LRGRP, alleles or related sequences.

Probes may also be used for the detection of related sequences and should preferably contain at least 50% of the nucleotides from any of these LRGRP encoding sequences. The hybridization probes of the subject invention may be derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements and introns of the naturally occurring LRGRP. Hybridization probes

may be labeled by a variety of reporter groups, including radionuclides such as ^{32}P or ^{35}S , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Other means for producing specific hybridization probes for DNAs encoding LRGRP include the cloning of nucleic acid sequences encoding LRGRP or LRGRP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides.

Polynucleotide sequences encoding LRGRP or portions thereof may be used for the diagnosis of conditions or diseases with which the expression of LRGRP is associated. For example, polynucleotide sequences encoding LRGRP may be used in hybridization or PCR assays of fluids or tissues from biopsies to detect LRGRP expression. The form of such qualitative or quantitative methods may include Southern or northern analysis, dot blot or other membrane-based technologies; PCR technologies; dip stick, pIN, chip and ELISA technologies. All of these techniques are well known in the art and are the basis of many commercially available diagnostic kits.

The nucleotide sequences encoding LRGRP disclosed herein provide the basis for assays that detect signal transduction events associated with disease states or condition such as obesity, diabetes, and reproductive disorders. The nucleotide sequence encoding LRGRP may be labeled by methods known in the art and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After an incubation period, the sample is washed with a compatible fluid which optionally contains a dye (or other label requiring a developer) if the nucleotide has been labeled with an enzyme. After the compatible fluid is rinsed off, the dye is quantitated and compared with a standard. If the amount of dye in the biopsied or extracted sample is significantly elevated over that of a comparable control sample, the nucleotide sequence has hybridized with nucleotide sequences in the sample, and the presence of elevated levels of nucleotide sequences encoding LRGRP in the sample indicates the presence of the associated disease or condition.

Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regime in animal studies, in clinical trials, or in monitoring the treatment of an

individual patient. In order to provide a basis for the diagnosis of disease, a normal or standard profile for LRGRP expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with LRGRP, or a portion thereof, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained for normal subjects with a dilution series of LRGRP run in the same experiment where a known amount of a substantially purified LRGRP is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients afflicted with LRGRP-associated diseases. Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established, a therapeutic agent is administered and a treatment profile is generated. Such assays may be repeated on a regular basis to evaluate whether the values in the profile progress toward or return to the normal or standard pattern. Successive treatment profiles may be used to show the efficacy of treatment over a period of several days or several months.

PCR, as described in US Patent Nos. 4,683,195 and 4,965,188, provides additional uses for oligonucleotides based upon the LRGRP sequence. Such oligomers are generally chemically synthesized, but they may be generated enzymatically or produced from a recombinant source. Oligomers generally comprise two nucleotide sequences, one with sense orientation (5'→3') and one with antisense (3'←5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Additionally, methods which may be used to quantitate the expression of a particular molecule include radiolabeling (Melby PC et al 1993 J Immunol Methods 159:235-44) or biotinylating (Duplax C et al 1993 Anal Biochem 229:36) nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated. Quantitation of multiple samples may be speeded up by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation. For example, the presence of a relatively high amount of LRGRP in extracts of biopsied tissues

may indicate the onset of diabetes, obesity, or reproductive disorders. A definitive diagnosis of this type may allow health professionals to begin aggressive treatment and prevent further worsening of the condition. Similarly, further assays can be used to monitor the progress of a patient during treatment. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known such as the triplet genetic code, specific base pair interactions, and the like.

Therapeutic Use of Polynucleotide Sequences

Based upon LRGRP's homology to genes encoding leptin receptor gene-related proteins that are believed to be membrane localized, its sharing of exons with the non-coding region of the leptin receptor, and its expression profile, polynucleotide sequences encoding LRGRP or antisense polynucleotides could provide the basis for diagnosis and treatment of disease states related to cancer, including lymphoma, leukemia, cancers of the lung, cervix, and bladder, or disorders in energy metabolism, development, connective tissues, or reproduction.

Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense polynucleotides of the gene encoding LRGRP. See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra).

The polynucleotides comprising full length cDNA sequence and/or its regulatory elements enable researchers to use sequences encoding LRGRP as an investigative tool in sense (Yousoufian H and HF Lodish 1993 Mol Cell Biol 13:98-104) or antisense (Eguchi et al (1991) Annu Rev Biochem 60:631-652) regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers, or larger fragments, can be designed from various locations along the coding or control regions.

Genes encoding LRGRP can be turned off by transfecting a cell or tissue with expression vectors which express high levels of a desired LRGRP-encoding fragment. Such constructs can flood cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases. Transient expression may

last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the control regions of gene encoding LRGRP, ie, the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, eg, between -10 and +10 regions of the leader sequence, are preferred. The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA were reviewed by Gee JE et al (In: Huber BE and BI Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco NY).

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding LRGRP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding LRGRP. Such DNA sequences may be

incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine and wybutosine as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Methods for introducing vectors into cells or tissues include those methods discussed *infra* and which are equally suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors are introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient is presented in US Patent Nos. 5,399,493 and 5,437,994, disclosed herein by reference. Delivery by transfection and by liposome are quite well known in the art.

Furthermore, the nucleotide sequences for LRGRP disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including but not limited to such properties as the triplet genetic code and specific base pair interactions.

Pharmaceutical Compositions

The present invention relates to pharmaceutical compositions which may comprise nucleotides, polypeptides, antibodies, agonists, antagonists, or inhibitors, alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. Any of these molecules can be administered to a patient alone, or in combination with other agents, drugs or hormones, in pharmaceutical compositions where it is mixed with excipient(s) or pharmaceutically acceptable carriers. In one embodiment of the present invention, the pharmaceutically acceptable carrier is pharmaceutically inert.

Administration of Pharmaceutical Compositions

Administration of pharmaceutical compositions is accomplished orally or parenterally. Methods of parenteral delivery include topical, intra-arterial (directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of "Remington's Pharmaceutical Sciences" (Maack Publishing Co, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, ie, dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules

made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations for parenteral administration include aqueous solutions of active compounds. For injection, the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

Manufacture and Storage

The pharmaceutical compositions of the present invention may be manufactured in a manner that known in the art, eg, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder in 1mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5 that is combined with buffer prior to use.

After pharmaceutical compositions comprising a compound of the invention formulated in an acceptable carrier have been prepared, they can be placed in an appropriate

container and labeled for treatment of an indicated condition. For administration of LRGRP, such labeling would include amount, frequency and method of administration.

Therapeutically Effective Dose

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, eg, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of protein or its antibodies, antagonists, or inhibitors which ameliorate the symptoms or condition. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, eg, ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Additional factors which may be taken into account include the severity of the disease state; age, weight and gender of the patient; diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long acting pharmaceutical compositions might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

INDUSTRIAL APPLICABILITY

I cDNA Library Construction

The hNT2 cell line exhibits characteristics of a committed neuronal precursor cell which is still at an early stage of development. The cDNA library for the untreated hNT2 cell line (HNT2NOT01, Cat. No. 937230) is available from Stratagene (Stratagene, La Jolla CA).

The library was constructed essentially as described below. Stratagene isolated the mRNA and prepared the cDNA library. cDNAs were primed using oligo d(T) and size fractionated to isolate fragments of 500 bp and larger. Synthetic adapter oligonucleotides were ligated onto the cDNA molecules enabling them to be inserted into the Uni-ZAP™ vector system (Stratagene). This allowed high efficiency unidirectional (sense orientation) lamda library construction and the convenience of a plasmid system with blue/white color selection to detect clones with cDNA insertions.

The quality of the cDNA library was screened using DNA probes, and then, the pBluescript™ phagemid (Stratagene) was excised. This phagemid allows the use of a plasmid system for easy insert characterization, sequencing, site-directed mutagenesis, the creation of unidirectional deletions and expression of fusion polypeptides. Subsequently, the custom constructed library phage particles were infected into *E. coli* host strain XL1-Blue™ (Stratagene). The high transformation efficiency of this bacterial strain increases the probability that the cDNA library contains rare, under-represented clones. Alternative unidirectional vectors include, but are not limited to, pcDNAI (Invitrogen, San Diego CA) and pSHlox-1 (Novagen, Madison WI).

II Isolation of cDNA Clones

The phagemid forms of individual cDNA clones were obtained by employing the

Miniprep Kit (Catalog No. 77468) available from Advanced Genetic Technologies Corp., Gaithersburg MD. This kit is in the 96-well format and provides enough reagents for 960 purifications. Each kit is provided with a recommended protocol, which was employed except for the following changes. First, the 96 wells were each filled with only 1 ml of sterile terrific broth with carbenicillin at 25 mg/L and glycerol at 0.4%. After the wells were inoculated, the bacteria were cultured for 24 hours and lysed with 60 µl of lysis buffer. A centrifugation step (2900 rpm for 5 minutes) was performed before the contents of the block were added to the primary filter plate. The optional step of adding isopropanol to TRIS buffer was not routinely performed. After the last step in the protocol, samples were transferred to a Beckman 96-well block for storage.

Alternatively, the *in vivo* excision process, in which the host bacterial strain is co-infected with both the library phage and an *fl* helper phage, for purifying phagemid. Polypeptides or enzymes derived from both the library-containing phage and the helper phage nicks the DNA, initiates new DNA synthesis from defined sequences on the target DNA, and creates a smaller, single stranded circular phagemid DNA molecule that includes all DNA sequences of the pBluescript phagemid and the cDNA insert. The phagemid DNA is released from the cells and purified, and used to reinfect fresh host cells (SOLR, Stratagene) where double stranded phagemid DNA is produced. Because the phagemid carries the gene for beta-lactamase, the newly transformed bacteria are selected on medium containing ampicillin.

Phagemid DNA may also be purified using the QIAWELL-8 Plasmid Purification System from the QIAGEN[™] DNA Purification System (QIAGEN Inc, Chatsworth CA). This product provides a convenient, rapid and reliable high-throughput method for lysing the bacterial cells and isolating highly purified phagemid DNA using QIAGEN anion-exchange resin particles with EMPORE[™] membrane technology from 3M in a multiwell format. The DNA was eluted from the purification resin and prepared for DNA sequencing and other analytical manipulations.

III Homology Searching of cDNA Clones and Their Deduced Proteins

Each cDNA was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems and incorporated into the INHERIT[™] 670 Sequence Analysis System. In this algorithm, Pattern Specification Language (TRW Inc, Los Angeles CA) was used to determine regions of homology. The three parameters that

determine how the sequence comparisons run were window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches. Smith-Waterman alignments were used to display the results of the homology search.

Peptide and protein sequence homologies were ascertained using the INHERIT™ 670 Sequence Analysis System in a way similar to that used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix homology plots were examined to distinguish regions of significant homology from chance matches.

BLAST, which stands for Basic Local Alignment Search Tool (Altschul SF (1993) J Mol Evol 36:290-300; Altschul, SF et al (1990) J Mol Biol 215:403-10), was used to search for local sequence alignments. BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs. BLAST is useful for matches which do not contain gaps. The fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).

An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user. The BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. The parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.

IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a

transcript of a gene and involves the hybridization of a labelled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al. supra).

Analogous computer techniques using BLAST (Altschul SF 1993 and 1990, supra) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte, Palo Alto CA). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

and it takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

Expression information was also obtained from reverse transcriptase PCR. Reverse transcription was performed on 1 µg total cellular RNA with Superscript reverse transcriptase (Gibco, BRL) using random hexamers in a 50 µl reaction. The primers P1 to P4 are 5'-AAGGCCGCGAGGCTCCCCATT-3', 5'-AGCAGCCGCGGCCCCAGTTC-3', 5'-TGACAAGTTAAACGCAGTTATCACAT-3', and 5'-TCTCTGCCTTCGGTCGAGTTG-3' respectively (Figure 8). The concentrations of the four primers are as follows: P1-500 nM, P2-250 nM, P3-500 nM, and P4-100 nM. The 50 µl PCR reaction contains 10 µl first-stand cDNA, 200 µM each dNTP, and 0.3U of Taq polymerase (Promega). The reaction conditions are as follows: 94° C for 3 min; 94° C 20 sec., 62° C 30 sec., and 72° C 30 sec. for 34 cycles; and 72° C for 4 min. The reaction products were visualized on an ethidium bromide stained agarose gel (Figure 9).

V Extension of LRGRP-Encoding Polynucleotides to Full Length or to Recover Regulatory Elements

Full length LRGRP-encoding nucleic acid sequence (SEQ ID NO:2) is used to design oligonucleotide primers for extending a partial nucleotide sequence to full length or

for obtaining 5' sequences from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers allow the extension of the known LRGRP-encoding sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest (US Patent Application 08/487,112, filed June 7, 1995, specifically incorporated by reference). The initial primers are designed from the cDNA using OLIGO® 4.06 Primer Analysis Software (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations is avoided.

The original, selected cDNA libraries, or a human genomic library are used to extend the sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary or desired, additional sets of primers are designed to further extend the known region.

By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR is performed using the Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the following parameters:

20	Step 1	94° C for 1 min (initial denaturation)
	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
	Step 4	94° C for 15 sec
	Step 5	65° C for 1 min
25	Step 6	68° C for 7 min
	Step 7	Repeat step 4-6 for 15 additional cycles
	Step 8	94° C for 15 sec
	Step 9	65° C for 1 min
	Step 10	68° C for 7:15 min
30	Step 11	Repeat step 8-10 for 12 cycles
	Step 12	72° C for 8 min
	Step 13	4° C (and holding)

A 5-10 µl aliquot of the reaction mixture is analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were

selected and cut out of the gel. Further purification involves using a commercial gel extraction method such as QIAQuick™ (QIAGEN Inc). After recovery of the DNA, Klenow enzyme was used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitate religation and cloning.

5 After ethanol precipitation, the products are redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase are added, and the mixture is incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) are transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook J et al, supra). After incubation for one hour
10 at 37° C, the whole transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook J et al, supra) containing 2xCarb. The following day, several colonies are randomly picked from each plate and cultured in 150 μ l of liquid LB/2xCarb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture is transferred into a non-sterile 96-well plate
15 and after dilution 1:10 with water, 5 μ l of each sample is transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer and one or both of the gene specific primers used for the extension reaction are added to each well. Amplification is performed using the following conditions:

20	Step 1	94° C for 60 sec
	Step 2	94° C for 20 sec
	Step 3	55° C for 30 sec
	Step 4	72° C for 90 sec
	Step 5	Repeat steps 2-4 for an additional 29 cycles
25	Step 6	72° C for 180 sec
	Step 7	4° C (and holding)

Aliquots of the PCR reactions are run on agarose gels together with molecular weight markers. The sizes of the PCR products are compared to the original partial cDNAs, and appropriate clones are selected, ligated into plasmid and sequenced.

30 VI Labeling and Use of Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs or mRNAs. In a preferred embodiment, hybridization probes are derived from sequences between nucleotides C₁₆₃ and A₈₇₄ of SEQ ID NO:2. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially

the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 mCi of [γ - 32 P] adenosine triphosphate (Amersham, Chicago IL) and T4 polynucleotide kinase (DuPont NEN[®], Boston MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 super fine resin column (Pharmacia). A portion containing 10⁷ counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II; DuPont NEN[®]).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR[™] film (Kodak, Rochester NY) is exposed to the blots in a Phosphorimager cassette (Molecular Dynamics, Sunnyvale CA) for several hours, hybridization patterns are compared visually.

VII Antisense Molecules

The LRGRP-encoding sequence, or any part thereof, is used to inhibit *in vivo* or *in vitro* expression of naturally occurring LRGRP. Although use of antisense oligonucleotides, comprising about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. An oligonucleotide based on the coding sequence of LRGRP, as shown in Figures 1A, 1B and 1C, is used to inhibit expression of naturally occurring LRGRP. The complementary oligonucleotide is designed from the most unique 5' sequence as shown in Figures 1A, 1B and 1C and used either to inhibit transcription by preventing promoter binding to the upstream nontranslated sequence or translation of an LRGRP-encoding transcript by preventing the ribosome from binding. Using an appropriate portion of the leader and 5' sequence of SEQ ID NO:2, an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the signal or early coding sequence of the polypeptide as shown in Figures 1A, 1B and 1C.

VIII Expression of LRGRP

Expression of the LRGRP is accomplished by subcloning the cDNAs into

appropriate vectors and transfecting the vectors into host cells. In this case, the cloning vector, pSport, previously used for the generation of the cDNA library is used to express LRGRP in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met and the subsequent 7 residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

Induction of an isolated, transfected bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first seven residues of β -galactosidase, about 5 to 15 residues of linker, and the full length LRGRP-encoding sequence. The signal sequence directs the secretion of LRGRP into the bacterial growth media which can be used directly in the following assay for activity.

An LRGRP fusion protein has been expressed in mammalian cells. The epitope tagged human LRGRP protein was used to show that cDNAs encoding LRGRP are likely to be translated into protein. Polynucleotides encoding an antigenic portion of c-myc protein were fused at the 3' end of polynucleotides encoding the entire LRGRP protein and inserted in a pcDNA3/CMV eukaryotic expression vector. The recombinant expression vector was introduced into COS-1 cells and immunofluorescence using anti-c-myc antibodies revealed expression of the predicted LRGRP fusion protein.

An LRGRP fusion protein has been expressed in bacterial cells. Polynucleotides encoding glutathione S-transferase (GST) were fused at the 3' end of polynucleotides encoding the entire LRGRP protein and inserted into an expression vector. The recombinant expression vector was introduced into *E. coli* and immunoblots using anti-LRGRP antibodies revealed expression of the predicted LRGRP fusion protein. Fusion proteins may be purified from lysed cells by absorption to glutathione-agarose beads followed by elution in the presence of free glutathione.

IX LRGRP Activity

LRGRP activity can be assayed by measuring its effect on leptin receptor activity. Leptin receptor has characteristic JAK tyrosine kinase binding sites (Lee GH et al, supra; Fukunaga R et al (1991) EMBO J 10:2855-2865). Activity of receptors which interact with JAK tyrosine kinases can be measured by evaluating ^{32}P incorporation into protein following stimulation with the appropriate ligand (for example Wang Y et al (1995) Mol

Endocrinol 9:303-311).

LRGRP's effect on leptin receptor activity can be assessed by measuring ³²P incorporation following addition of leptin in cell lines transfected with leptin receptor expression constructs with or without co-transfection with LRGRP expression constructs. Immunoprecipitation with antibodies to P-tyrosine is followed by gel electrophoresis, and blotting. Protein phosphorylation is quantitated by measuring radiation in the size separated proteins with or without LRGRP expression construct co-transfection.

X Production of LRGRP Specific Antibodies

LRGRP substantially purified using PAGE electrophoresis (Sambrook, supra) is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence translated from LRGRP is analyzed using DNASTar software (DNASTar Inc) to determine regions of high immunogenicity and a corresponding oligopolypeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Analysis to select appropriate epitopes, such as those near the C-terminus or in hydrophilic regions (shown in Figures 5 and 6) is described by Ausubel FM et al (supra).

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel FM et al, supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

Antisera to LRGRP has been generated. The following two peptides were chemically synthesized: FLAKRVTYDSDAC, found within LRGRP from amino acid residue 51 to 62, and KFGRGDDFSWEQW, representing LRGRP amino acid residues 120 to 131. Each of these peptides were injected into rabbits and anti-LRGRP antisera was later collected by established procedures.

XI Purification of Naturally Occurring LRGRP Using Specific Antibodies

Naturally occurring or recombinant LRGRP is substantially purified by immunoaffinity chromatography using antibodies specific for LRGRP. An immunoaffinity column is constructed by covalently coupling LRGRP antibody to an activated

41

chromatographic resin such as CNBr-activated Sepharose (Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing LRGRP is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of LRGRP (eg, high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/LRGRP binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and LRGRP is collected.

XII Identification of Molecules Which Interact with LRGRP

LRGRP, or biologically active fragments thereof, are labelled with ¹²⁵I Bolton-Hunter reagent (Bolton, AE and Hunter, WM (1973) Biochem J 133:529). Candidate molecules previously arrayed in the wells of a 96 well plate are incubated with the labelled LRGRP, washed and any wells with labelled LRGRP complex are assayed. Data obtained using different concentrations of LRGRP are used to calculate values for the number, affinity, and association of LRGRP with the candidate molecules.

Molecules that bind to LRGRP may be identified by immunoprecipitation using antisera specific to LRGRP. LRGRP immunoprecipitate is run on a polyacrylamide gel under non-denaturing conditions using standard techniques. Proteins on the gel with a higher predicted molecular weight than LRGRP may be heteromers of LRGRP and LRGRP-interacting proteins. These LRGRP-interacting proteins may be purified and characterized further. In addition, interaction with OB-R may be examined directly by immunoprecipitation of cell extracts with OB-R antisera followed by Western blot analysis with LRGRP antisera.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: INCYTE PHARMACEUTICALS, INC.
- (ii) TITLE OF THE INVENTION: A NOVEL HUMAN LEPTIN RECEPTOR GENE-RELATED PROTEIN
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 - (B) STREET: 3174 Porter Drive
 - (C) CITY: Palo Alto
 - (D) STATE: CA
 - (E) COUNTRY: U.S.
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ Version 1.5
- (vi) CURRENT APPLICATION DATA:
 - (A) PCT APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: Herewith
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/691,071
 - (B) FILING DATE: 1-AUG-1996
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/843,370
 - (B) FILING DATE: 15-APR-1997
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Billings, Lucy J.
 - (B) REGISTRATION NUMBER: 36,749
 - (C) REFERENCE/DOCKET NUMBER: PF-0111-1 PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 415-855-0555
 - (B) TELEFAX: 415-845-4166

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 131 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY: HNT2NOT01
 - (B) CLONE: 492703
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Met Ala Gly Val Lys Ala Leu Val Ala Leu Ser Phe Ser Gly Ala Ile
 1           5           10           15
Gly Leu Thr Phe Leu Met Leu Gly Cys Ala Leu Glu Asp Tyr Gly Val
          20           25           30
Tyr Trp Pro Leu Phe Val Leu Ile Phe His Gly Ile Ser Pro Ile Pro
          35           40           45
His Phe Ile Ala Lys Arg Val Thr Tyr Asp Ser Asp Ala Thr Ser Ser
          50           55           60
Ala Cys Arg Glu Leu Ala Tyr Phe Phe Thr Thr Gly Ile Val Val Ser
65           70           75           80
Ala Phe Gly Phe Pro Val Ile Leu Ala Arg Val Ala Val Ile Lys Trp
          85           90           95
Gly Ala Cys Gly Leu Val Leu Ala Gly Asn Ala Val Ile Phe Leu Thr
          100          105          110
Ile Gln Gly Phe Phe Leu Ile Phe Gly Arg Gly Asp Asp Phe Ser Trp
          115          120          125
Glu Gln Trp
          130

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 874 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: HNT2NOT01
- (B) CLONE: 492703

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

GTCTGGCTTG GGCAGGCTGC CCGGGCCGTG GCAGGAAGCS GGAAGCAGCC GCGGCCCCAG      60
TTCGGGAGAC ATGGCGGGCG TTAAAGCTCT CGTGGCATT TCC TTCAGTG GGGCTATTGG      120
ACTGACTTTT CTTATGCTGG GATGTGCCTT AGAGGATTAT GGCGTTTACT GGCCCTTATT      180
CGTCCTGATT TTCCACGGCA TCTCCCCCAT CCCCATTTC ATTGCCAAA GAGTCACCTA      240
TGA CTGAGAT GCAACCAGTA GTGCCGTGCG GGAAC TGGA TATTTCTTCA CTACTGGAAT      300
TGTTGTTTCT GCCTTTGGAT TTCCTGTTAT TCTTGCTCGT GTGGCTGTGA TCAAATGGGG      360
AGCCTGCGGC CTTGTGTTGG CAGGCAATGC AGTCATTTTC CTTACAATTC AAGGGTTTTT      420
CCTTATATTT GGAAGAGGAG ATGATTTTAG CTGGGAGCAG TGGTAGCACT TTATTCTGAT      480
TACAGTGCAT TGAATTTCTT AGAACTCATA CTATCTGTAT ACATGTGCAC ATGCGGCATT      540
TTACTATGAA ATTTAATATG CTGGGTTTTT TAATACCTTT ATATATCATG TTCACTTTAA      600
GAAAGACTTC ATAAGTAGGA GATGAGTTTT ATTCTCAGCA AATAGACCTG TCAAATTTAG      660
ATTATGTTAC TCAAATTATG TTA CTGTTT GGCTGTTT CAT GTAGTCACGG TGCTCTCAGA      720
AAATATATTA ACGCAGTCTT GTAGGCAGCT GCCACCTTAT GCAGTGCATC GAAACCTTTT      780
GCTTGGGGAT GTGCTTGGAG AGGCAGATAA CGCTGAAGCA GGCCTCTCAT GACCCAGGAA      840
GGCCGGGGTG GWTCCCTCTT TKTTTGTAG TCCA                                874

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 145 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank

(B) CLONE: 733888

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Cys Cys His Ile His Ile Gln Cys Phe Asp Cys Cys Ser Met Lys
 1           5           10           15
Asn Thr Ile Leu Ala Val Ala Ala Leu Ala Phe Ala Gly Val Val Gly
          20           25           30
Leu Thr Phe Leu Val Leu Gly Cys Ala Leu Pro Arg Tyr Gly Thr Trp
          35           40           45
Thr Pro Met Phe Val Ile Thr Phe Tyr Val Leu Ser Pro Val Pro Leu
          50           55           60
Leu Ile Ala Arg Arg Phe Gln Glu Asp Met Thr Gly Thr Asn Ala Cys
65           70           75           80
Ile Glu Leu Ala Leu Phe Ile Thr Thr Gly Ile Val Ile Ser Ala Phe
          85           90           95
Ala Leu Pro Ile Val Leu Ala His Ala Gly Thr Ile Ala Met Ser Ala
          100          105          110
Cys Phe Leu Ile Phe Ile Ala Asn Ser Ile Asn Phe Ser Val Ile Ile
          115          120          125
Phe Tyr Phe Arg Ile Phe Asn Gly Glu Asp Met Asn Gly Met Ser Leu
130          135          140
Trp
145

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 140 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank

(B) CLONE: 1197072

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Met Glu Phe Lys Val Ser Pro Leu Thr Lys Ile Ile Ser Leu Ser
 1           5           10           15
Gly Phe Leu Ala Leu Gly Phe Leu Leu Val Ile Leu Ser Cys Ala Leu
          20           25           30
Phe His Asn Tyr Tyr Pro Leu Phe Asp Ile Leu Ile Phe Leu Leu Ala
          35           40           45
Pro Ile Pro Asn Thr Ile Phe Asn Ala Gly Asn Lys Tyr His Thr Ser
          50           55           60
Asp Phe Met Ser Asp Ser Ser Asn Thr Gly Gln Asp Leu Ala His Phe
65           70           75           80
Leu Thr Gly Met Leu Val Thr Ser Gly Ile Ala Leu Pro Val Val Phe
          85           90           95
Tyr His Cys Gln Leu Ile Gly His Leu Ser Cys Ile Met Cys Met Ile
          100          105          110
Gly Gly Leu Ile Ile Tyr Ser Ser Ile Val Ile Phe Lys Trp Phe Phe
          115          120          125
Lys Lys Asp Phe Asn Glu Asp Asp Ser Leu Phe Gly
130          135          140

```

CLAIMS

1. A substantially purified human leptin receptor gene-related protein comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.
2. The substantially purified fragment of claim 1 from Met₂₂ to Trp₁₃₁.
- 5 3. An isolated and purified polynucleotide sequence encoding a polypeptide of claim 1.
4. The isolated and purified polynucleotide sequence of claim 3 from nucleotides C₁₆₃ to A₈₇₄ of SEQ ID NO:2, inclusive.
5. An isolated and purified polynucleotide sequence of claim 3 consisting of the
10 sequence of SEQ ID NO:2 or degenerate variants thereof.
6. A polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 4.
7. A polynucleotide sequence fully complementary to the sequence of SEQ ID NO:2 or degenerate variants thereof.
- 15 8. An isolated and purified polynucleotide sequence of claim 4 consisting of a polynucleotide sequence that hybridizes under stringent hybridization conditions to the sequence of SEQ ID NO:2.
9. A recombinant expression vector containing a polynucleotide sequence of claim 5.
10. A recombinant host cell comprising a polynucleotide sequence of claim 5.
- 20 11. A method for producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:1, the method comprising the steps of:
 - a) culturing the host cell of Claim 10 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.
- 25 12. A purified antibody which binds specifically to a polypeptide of claim 1.
13. A purified agonist which specifically binds to and modulates the activity of the polypeptide of claim 1.
14. A purified antagonist which specifically binds to and modulates the activity of the polypeptide of claim 1.
- 30 15. A pharmaceutical composition comprising a substantially purified polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

16. A method for treating a metabolic disorder comprising administering to a subject in need of such treatment an effective amount of the agonist of claim 13.

17. A method for treating a reproductive disorder comprising administering to a subject in need of such treatment an effective amount of the agonist of claim 13.

5 18. A method for treating a developmental disorder comprising administering to a subject in need of such treatment an effective amount of the agonist of claim 13.

19. A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 14.

10 20. A method for treating a connective tissue disorder comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 14.

21. A method for detecting a polynucleotide which encodes human leptin receptor gene-related protein in a biological sample comprising the steps of:

a) hybridizing the polynucleotide of claim 6 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and

15 b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding human leptin receptor gene-related protein in said biological sample.

1/11

```

          9      18      27      36      45      54
5' TCT GGC TTG GGC AGG CTG CCC GGC CCG TGG CAG GAA GCS GGA AGC AGC CGC GGC

          63      72      81      90      99      108
CCC AGT TCG GGA GAC ATG GCG GGC GTT AAA GCT CTC GTG GCA TTA TCC TTC AGT
      M A G V K A L V A L S F S

          117      126      135      144      153      162
GGG GCT ATT GGA CTG ACT TTT CTT ATG CTG GGA TGT GCC TTA GAG GAT TAT GGC
G A I G L T F L M L G C A L E D Y G

          171      180      189      198      207      216
GTT TAC TGG CCC TTA TTC GTC GTC ATT TTC CAC GGC ATC TCC CCC ATC CCC CAT
V Y W P L F V V L I F H G I S P I P H

          225      234      243      252      261      270
TTC ATT GCC AAA AGA GTC ACC TAT GAC TCA GAT GCA ACC AGT AGT GCC TGT CGG
F I A K R V T Y D S D A T S S A C R

          279      288      297      306      315      324
GAA CTG GCA TAT TTC TTC ACT ACT GGA ATT GTT GTT TCT GCC TTT GGA TTT CCT
E L A Y F F T T G I V V S A F G F P

```

FIGURE 1A

2/11

333	342	351	360	369	378
GTT ATT CTT GCT CGT GTG GCT GTG ATC AAA TGG GGA GCC TGC GGC CTT GTG TTG					
V I L A R V A V A V I K W G A C G L V L					
387	396	405	414	423	432
GCA GGC AAT GCA GTC ATT TTC CTT ACA ATT CAA GGG TTT TTC CTT ATA TTT GGA					
A G N A V I I F L T I Q G F F L I F G					
441	450	459	468	477	486
AGA GGA GAT GAT TTT AGC TGG GAG CAG TGG TAG CAC TTT ATT CTG ATT ACA GTG					
R G D D F S W E Q W					
495	504	513	522	531	540
CAT TGA ATT TCT TAG AAC TCA TAC TAT CTG TAT ACA TGT GCA CAT GCG GCA TTT					
549	558	567	576	585	594
TAC TAT GAA ATT TAA TAT GCT GGT GGG TTT TTT AAT ACC TTT ATA TAT CAT GTT CAC					
603	612	621	630	639	648
TTT AAG AAA GAC TTC ATA AGT AGG AGA TGA GTT TTA TTC TCA GCA AAT AGA CCT					

FIGURE 1B

3/11

657	666	675	684	693	702
GTC AAA TTT AGA TTA TGT TAC TCA AAT TAT GTT ACT TGT TTG GCT GTT CAT GTA					
711	720	729	738	747	756
GTC ACG GTG CTC TCA GAA AAT ATA TTA ACG CAG TCT TGT AGG CAG CTG CCA CCT					
765	774	783	792	801	810
TAT GCA GTG CAT CGA AAC CTT TTG CTT GGG GAT GTG CTT GGA GAG GCA GAT AAC					
819	828	837	846	855	864
GCT GAA GCA GGC CTC TCA TGA CCC AGG AAG GCC GGG GTG GWT CCC TCT TTK TTT					
873					
TGT AGT CCA 3'					

FIGURE 1C


4/11

The Electronic Northern for Clone: 492703
and Stringency >= 50

Library	Lib Description	Abun	Pct Abun
RATRN0T01	heart, right atrium, 51 F	1	0.0861
SYNORAB01	synovium, hip, rheumatoid, 68 F	4	0.0779
LIVRNOM01	liver, 49 M, WM	1	0.0254
PLACNOB01	placenta, neonatal F	1	0.0225
BRSTN0T01	breast, 56 F	1	0.0192
HNT2AGT01	hNT-2 cell line, post-mitotic neurons	1	0.0190
HNT2N0T01	hNT-2 cell line, teratocarcinoma, control	1	0.0172
BRSTTUT03	breast tumor, 58 F, match to BRSTN0T05	1	0.0148
COLNFET02	colon, fetal F	1	0.0142
UCMCL5T01	lymphocytes (umbilical cord), treated IL-5	1	0.0125
MELANOM01	melanocytes, M, NORM, WM	1	0.0108
PLACNOM02	placenta, neonatal F, NORM, WM	1	0.0056

FIGURE 2

5/11



* Numbering relative to human leptin receptor
Hatched area represents identical sequences

FIGURE 3

7/11




FIGURE 5

8/11





FIGURE 6

Human genomic organization of OB-RGRP



Exon/Intron junctions of OB-RGRP gene

MetAlaGlyValLysA ATGGCGGGCGTTAAAGgtacatcgcg	INTRON 1 4.3 KB	laLeuValAlaLeuSer cttttggtttatttttcacagCTCTCGTGGCATTATCC
AlaLeuGluAspTyrGl GCCTTAGAGGATTATGGgtaagtt	INTRON 2 4.5 KB	yValTyrTrpProLeu (t)10ggattttgacctgggtccaaactgacagCGTTTACTGCCCCCTTA
LeuAlaArgValAlaVal CTTGCTCGTGTGGCTGTGgtaagttt	INTRON 3 2.0 KB	IleLysTrpGlyAla tcctctttttcttctgtcttttcagATCAAAATGGGGAGCCC

FIGURE 7

10/11




FIGURE 8

11/11

BEST AVAILABLE COPY




FIGURE 9

Applicant(s): JOCKERS, et al.
Serial No.: 10/774,721
Filing Date: 2/9/2004
Docket No.: FRAV2003/0005 US NP
PRIOR ART